Literature DB >> 7636255

Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA.

G Mor1, D M Klinman, S Shapiro, E Hagiwara, M Sedegah, J A Norman, S L Hoffman, A D Steinberg.   

Abstract

The number, type, and location of cytokine- and Ab-secreting cells activated in mice immunized and boosted with plasmid DNA encoding the circumsporozoite protein of the malarial parasite Plasmodium yoelii (PyCSP) were monitored. The initial humoral response was localized to the draining lymph nodes and was characterized by production of IgG1 anti-PyCSP Abs and the Th2 cytokine IL-4. In contrast, the secondary response was dominated by IFN-gamma production (a Th1 cytokine) and the secretion of IgG2a anti-PyCSP Abs in the spleen. PyCSP DNA and mRNA were detected only in the quadriceps muscles (sites of plasmid injection), yet these sites lacked either cytokine- or Ab-secreting cells. These findings indicate that circulating lymphocytes encounter plasmid-encoded Ag in the muscle bed, initiate a humoral response in the draining lymph nodes, and then seed distal lymphoid organs. Profound differences were observed between the primary and secondary immune responses induced by plasmid immunization, which may influence vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636255

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Authors:  D M Klinman; S Kamstrup; D Verthelyi; I Gursel; K J Ishii; F Takeshita; M Gursel
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Plasmid DNA vaccines. Immunology, tolerance, and autoimmunity.

Authors:  G Mor; M Eliza
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

3.  Immunization with structural and non-structural proteins of Theiler's murine encephalomyelitis virus alters demyelinating disease.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neurovirol       Date:  2012-03-09       Impact factor: 2.643

4.  DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state.

Authors:  M Mancini; M Hadchouel; H L Davis; R G Whalen; P Tiollais; M L Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

5.  Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein.

Authors:  R Weiss; W W Leitner; S Scheiblhofer; D Chen; A Bernhaupt; S Mostböck; J Thalhamer; J A Lyon
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 6.  DNA vaccines: safety and efficacy issues.

Authors:  D M Klinman; M Takeno; M Ichino; M Gu; G Yamshchikov; G Mor; J Conover
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Number of specific antibody-secreting cells in the peripheral blood among children with mycoplasma pneumonia.

Authors:  M Iseki; T Takahashi; K Kimura; R Yamashita; T Sasaki
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

8.  Role of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoprotein.

Authors:  C M Boyle; M Morin; R G Webster; H L Robinson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

9.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

Review 10.  FDA guidance on prophylactic DNA vaccines: analysis and recommendations.

Authors:  Dennis M Klinman; Sven Klaschik; Debra Tross; Hidekazu Shirota; Folkert Steinhagen
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.